Gilead Sciences (NASDAQ:GILD) Rating Reiterated by Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by investment analysts at Royal Bank of Canada in a report released on Wednesday, TipRanks reports. They presently have a $83.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would suggest a potential upside of 12.37% from the company’s current price.

A number of other equities analysts have also recently issued reports on the company. Barclays assumed coverage on Gilead Sciences in a report on Thursday, February 27th. They issued an “underweight” rating and a $62.00 target price for the company. HC Wainwright cut Gilead Sciences from a “buy” rating to a “neutral” rating in a report on Monday, March 2nd. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Sunday, February 9th. Sanford C. Bernstein cut Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $78.00 to $70.00 in a report on Thursday, February 6th. Finally, SunTrust Banks reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $78.08.

Shares of GILD opened at $73.86 on Wednesday. Gilead Sciences has a 1 year low of $60.89 and a 1 year high of $85.97. The company has a current ratio of 3.10, a quick ratio of 3.01 and a debt-to-equity ratio of 1.02. The stock has a 50 day simple moving average of $71.41 and a 200-day simple moving average of $66.60. The stock has a market cap of $93.33 billion, a PE ratio of 17.54, a PEG ratio of 5.79 and a beta of 0.99.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.37). Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. The company had revenue of $5.88 billion during the quarter, compared to analyst estimates of $5.74 billion. During the same period in the previous year, the company posted $1.44 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences will post 6.03 EPS for the current fiscal year.

In other news, Director John Francis Cogan sold 2,413 shares of Gilead Sciences stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $75.27, for a total value of $181,626.51. Following the completion of the sale, the director now directly owns 57,273 shares of the company’s stock, valued at approximately $4,310,938.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 2,950 shares of Gilead Sciences stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $64.63, for a total value of $190,658.50. Following the completion of the sale, the executive vice president now directly owns 20,014 shares of the company’s stock, valued at $1,293,504.82. The disclosure for this sale can be found here. Insiders sold a total of 73,532 shares of company stock valued at $5,101,386 over the last three months. Insiders own 0.20% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ilmarinen Mutual Pension Insurance Co bought a new position in shares of Gilead Sciences in the 3rd quarter worth $10,711,000. Colony Group LLC boosted its position in shares of Gilead Sciences by 4.8% in the 3rd quarter. Colony Group LLC now owns 66,536 shares of the biopharmaceutical company’s stock worth $4,217,000 after purchasing an additional 3,018 shares during the last quarter. Voya Investment Management LLC boosted its position in shares of Gilead Sciences by 29.6% in the 3rd quarter. Voya Investment Management LLC now owns 2,436,740 shares of the biopharmaceutical company’s stock worth $154,441,000 after purchasing an additional 556,936 shares during the last quarter. Voya Financial Advisors Inc. boosted its position in shares of Gilead Sciences by 232.7% in the 3rd quarter. Voya Financial Advisors Inc. now owns 18,224 shares of the biopharmaceutical company’s stock worth $1,146,000 after purchasing an additional 12,747 shares during the last quarter. Finally, Redpoint Investment Management Pty Ltd boosted its position in shares of Gilead Sciences by 4.2% in the 3rd quarter. Redpoint Investment Management Pty Ltd now owns 100,929 shares of the biopharmaceutical company’s stock worth $6,397,000 after purchasing an additional 4,083 shares during the last quarter. 80.32% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Outstanding Shares

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.